نتائج البحث - "Johanna C. Bendell"

المصدر: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for immunotherapy of cancer, 9(7):002446. BMC

مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, Gastroenterology, B7-H1 Antigen, 0302 clinical medicine, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Immunology and Allergy, Prodrugs, Immune Checkpoint Inhibitors, RC254-282, Clinical/Translational Cancer Immunotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Antibodies, Monoclonal, Middle Aged, Oncology, Tolerability, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Toxicity, Molecular Medicine, Female, immunotherapy, medicine.drug, Adult, CTLA-4 antigen, medicine.medical_specialty, Combination therapy, Immunology, therapies, Ipilimumab, investigational, 03 medical and health sciences, Internal medicine, medicine, Humans, Testicular cancer, Pneumonitis, Aged, Pharmacology, Dose-Response Relationship, Drug, business.industry, medicine.disease, 030104 developmental biology, NIVOLUMAB PLUS IPILIMUMAB, PD-L1 inhibitor, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f59b5f6c6c998d04c0063e8f4efa570Test
https://pubmed.ncbi.nlm.nih.gov/34301808Test

5

A phase I study of an IDO-1 inhibitor (LY3381916) as monotherapy and in combination with an anti-PD-L1 antibody (LY3300054) in patients with advanced cancer

المؤلفون: Anna M. Szpurka, Sandaruwan Geeganage, Johanna C. Bendell, Johan Wallin, Shadia I. Jalal, Sylvie Rottey, Karim A. Benhadji, Hans Prenen, Leena Gandhi, Thompson N. Doman, Violeta Regnier Galvao, Nuria Kotecki, Subha Suriyapperuma, Meng Xia, Abhijoy Saha, P. Vuagnat, Xiaojian Xu, Bert H. O'Neil

المصدر: Journal of immunotherapy (Hagerstown, Md. : 1997)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4baec1e12f207c37e1d3693c803fac61Test
https://hdl.handle.net/10067/1804940151162165141Test

6

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies

المؤلفون: Herbert Hurwitz, Vaibhav Sahai, Chris Verslype, Jason Clark, Johanna C. Bendell, Ashwin Reddy Sama, Eric Van Cutsem, Manuel Hidalgo, Edward W Greeno, Eileen M. O'Reilly, Chung Pin Li, Kenneth H. Yu, Christopher James Walker, Fitzroy Dawkins, Teresa Macarulla, Marcelo Garrido Salvo

المصدر: Investigational New Drugs. 36:683-695

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Ruxolitinib, Placebo, Disease-Free Survival, Article, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Pancreatic cancer, Antineoplastic Combined Chemotherapy Protocols, Nitriles, medicine, Clinical endpoint, Humans, Pharmacology (medical), Aged, Aged, 80 and over, Pharmacology, business.industry, Hazard ratio, Janus Kinase 1, Janus Kinase 2, Middle Aged, medicine.disease, Chemotherapy regimen, Pancreatic Neoplasms, Clinical trial, Pyrimidines, 030104 developmental biology, 030220 oncology & carcinogenesis, Disease Progression, Pyrazoles, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4efb9dd95fab56ab09c97a08030248fTest
https://doi.org/10.1007/s10637-018-0580-2Test

7

Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers

المؤلفون: Erika Hamilton, Hani Gabra, Kathleen M. Moore, Jennifer R. Diamond, Mark Poole, D. Ross Camidge, Martin D. Forster, Michael S. Gordon, David M. Waterhouse, Barbara A. Goff, Carolyn D. Britten, Johanna C. Bendell

المصدر: Invest New Drugs

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, Mitochondrial inhibitor, Cell, Uterine Cervical Neoplasms, Neutropenia, Article, Drug Administration Schedule, 03 medical and health sciences, 0302 clinical medicine, Stable Disease, Pharmacokinetics, Ovarian cancer, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, ME-344, Pharmacology (medical), Oncology & Carcinogenesis, Aged, Ovarian Neoplasms, Pharmacology, Lung, Dose-Response Relationship, Drug, Small cell lung cancer, business.industry, Middle Aged, medicine.disease, Isoflavones, Mitochondria, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Toxicity, Female, 1115 Pharmacology And Pharmaceutical Sciences, Topotecan, Neoplasm Recurrence, Local, Topoisomerase I Inhibitors, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14dee4e7e022a14638395d5059e46ddfTest
https://doi.org/10.1007/s10637-017-0444-1Test

8

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C

المؤلفون: Jean-Luc Van Laethem, Frederico Longo Muñoz, Thea Kalebic, Khaldoun Almhanna, Maria Alsina, Carolina Muriel Lopez, Antonio Cubillo Gracian, Hadi Danaee, Irfan Firdaus, Zhan Ye, Adedigbo Fasanmade, Johanna C. Bendell, Wells A. Messersmith, David Wright, Richard A. Hubner, Maria Luisa Limon Miron

المصدر: Investigational New Drugs. 35:235-241

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, medicine.medical_specialty, Immunoconjugates, Esophageal Neoplasms, Receptors, Enterotoxin, Phases of clinical research, Antineoplastic Agents, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Neutropenia, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Stomach Neoplasms, Internal medicine, medicine, Humans, Pharmacology (medical), Gastrointestinal cancer, Aged, Aged, 80 and over, Pharmacology, business.industry, Guanylate cyclase 2C, Middle Aged, medicine.disease, Interim analysis, Tumor Burden, Surgery, Treatment Outcome, 030104 developmental biology, Oncology, Monomethyl auristatin E, chemistry, 030220 oncology & carcinogenesis, Female, Esophagogastric Junction, Neoplasm Recurrence, Local, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15e4a2ebe65fb4b73b1a74204841d4eaTest
https://doi.org/10.1007/s10637-017-0439-yTest

9

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer

المساهمون: MUMC+: DA KFT Medische Staf (9), RS: FHML non-thematic output, Medical Oncology

المصدر: Cancer Discovery, 7(6), 610-619. American Association for Cancer Research Inc.
Cancer discovery, vol 7, iss 6
Cancer Discovery, 7(6), 610. American Association for Cancer Research Inc.

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Colorectal cancer, Medizin, Cetuximab, Raf Kinase Inhibitor, Pharmacology, 0302 clinical medicine, Encorafenib, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Phosphoinositide-3 Kinase Inhibitors, Cancer, Aged, 80 and over, Sulfonamides, COLON-CANCER, Middle Aged, Clinical Trial, Colo-Rectal Cancer, 3. Good health, Multicenter Study, Tolerability, 6.1 Pharmaceuticals, 030220 oncology & carcinogenesis, Female, Colorectal Neoplasms, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Maximum Tolerated Dose, EGFR, Oncology and Carcinogenesis, BIOMARKERS, INHIBITION, Antineoplastic Agents, Disease-Free Survival, Clinical Trial, Phase I, 03 medical and health sciences, Phase I, SDG 3 - Good Health and Well-being, Clinical Research, Internal medicine, MAPK PATHWAY, medicine, Journal Article, KRAS, Humans, WILD-TYPE, neoplasms, Protein Kinase Inhibitors, Aged, business.industry, Evaluation of treatments and therapeutic interventions, RAF, medicine.disease, digestive system diseases, FLUOROURACIL, Clinical trial, Thiazoles, 030104 developmental biology, Concomitant, Mutation, GENE COPY NUMBER, Carbamates, Phosphatidylinositol 3-Kinase, Digestive Diseases, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a74efca771fba8318569827a37a712fTest
https://hdl.handle.net/1765/108310Test

10

A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms

المؤلفون: John Nemunaitis, Luis Paz-Ares, Amit Mahipal, Shaoyi Li, Pamela N. Munster, Tim Meyer, Hans A. de Haan, Kristen Hege, Monica M. Mita, Johanna C. Bendell, Edward M. Wolin, Ellen Filvaroff, Alain C. Mita

المساهمون: Deming, Dustin A

المصدر: PLoS ONE
PloS one, vol 14, iss 9
Repisalud
Instituto de Salud Carlos III (ISCIII)
PLoS ONE, Vol 14, Iss 9, p e0221994 (2019)

مصطلحات موضوعية: 0301 basic medicine, Male, Physiology, Kinase Inhibitors, Cancer Treatment, Phases of clinical research, Administration, Oral, Neuroendocrine tumors, Toxicology, Pathology and Laboratory Medicine, Gastroenterology, Biochemistry, Cohort Studies, 0302 clinical medicine, Drug Metabolism, Medicine and Health Sciences, Enzyme Inhibitors, Stomatitis, Cancer, Gastrointestinal Neoplasms, Multidisciplinary, Middle Aged, Body Fluids, Neuroendocrine Tumors, Blood, Tolerability, Oncology, Research Design, 6.1 Pharmaceuticals, 030220 oncology & carcinogenesis, Pyrazines, Administration, Toxicity, Medicine, Female, Anatomy, Research Article, Oral, Adult, Diarrhea, medicine.medical_specialty, Maximum Tolerated Dose, General Science & Technology, Clinical Research Design, Science, Carcinoid Tumor, Mechanistic Target of Rapamycin Complex 2, Gastroenterology and Hepatology, Mechanistic Target of Rapamycin Complex 1, Research and Analysis Methods, 03 medical and health sciences, Rare Diseases, Signs and Symptoms, Pharmacokinetics, Refractory, Clinical Research, Diagnostic Medicine, Internal medicine, medicine, Humans, Adverse effect, Aged, Pharmacology, business.industry, Evaluation of treatments and therapeutic interventions, Biology and Life Sciences, medicine.disease, 030104 developmental biology, Enzymology, Adverse Events, Digestive Diseases, business, Biomarkers

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71c063f01d24cfba07ad4d4f15e01acfTest
https://pubmed.ncbi.nlm.nih.gov/31527867Test

تنقيح النتائج